Zydus Lifesciences
- Advice
- Hold
Zydus Lifesciences Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Zydus Lifesciences
Start SIPZydus Lifesciences Investment Rating
-
Master Rating:
-
Zydus Lifesciences has an operating revenue of Rs. 16,433.50 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 19% is great, ROE of 26% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 21% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|
Oper Rev Qtr Cr | 2,087 | 2,217 | 1,981 | 1,919 |
Operating Expenses Qtr Cr | 1,628 | 1,720 | 1,437 | 1,562 |
Operating Profit Qtr Cr | 459 | 679 | 544 | 458 |
Depreciation Qtr Cr | 122 | 124 | 123 | 123 |
Interest Qtr Cr | 89 | 64 | 41 | 42 |
Tax Qtr Cr | 129 | 149 | 101 | 100 |
Net Profit Qtr Cr | 256 | 451 | 332 | 247 |
Zydus Lifesciences Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- 437.03
- 50 Day
- 428.15
- 100 Day
- 416.39
- 200 Day
- 409.89
- 20 Day
- 440.41
- 50 Day
- 424.97
- 100 Day
- 415.44
- 200 Day
- 387.96
Zydus Lifesciences Resistance and Support
Resistance | |
---|---|
First Resistance | 482.12 |
Second Resistance | 494.09 |
Third Resistance | 511.67 |
RSI | 69.91 |
MFI | 67.2 |
MACD Single Line | 3.68 |
MACD | 4.66 |
Support | |
---|---|
First Resistance | 452.57 |
Second Resistance | 434.99 |
Third Resistance | 423.02 |
Zydus Lifesciences Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 1,650,400 | 42,860,888 | 25.97 |
Week | 1,052,458 | 36,709,742 | 34.88 |
1 Month | 1,200,092 | 52,444,027 | 43.7 |
6 Month | 1,352,271 | 55,483,669 | 41.03 |
Zydus Lifesciences Result Highlights
Zydus Lifesciences Synopsis
NSE-Medical-Generic Drugs
Zydus Lifesciences is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 7981.90 Cr. and Equity Capital is Rs. 102.40 Cr. for the Year ended 31/03/2022. Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC025878 and registration number is 025878.Market Cap | 48,485 |
Sales | 8,486 |
Shares in Float | 25.31 |
No of funds | 218 |
Yield | 0.53 |
Book Value | 3.64 |
U/D Vol ratio | 1.8 |
LTDebt / Equity | 1 |
Alpha | 0.08 |
Beta | 0.81 |
Zydus Lifesciences
Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
---|---|---|---|---|
Promoters | 74.98% | 74.98% | 74.88% | |
Mutual Funds | 5.56% | 5.36% | 4.62% | |
Insurance Companies | 7.87% | 7.3% | 7.3% | |
Foreign Portfolio Investors | 2.52% | 2.61% | 2.86% | |
Financial Institutions/ Banks | 0.01% | |||
Individual Investors | 7.04% | 7.6% | 8.02% | |
Others | 2.03% | 2.14% | 2.32% |
Zydus Lifesciences Management
Name | Designation |
---|---|
Mr. Pankaj R Patel | Chairman |
Dr. Sharvil P Patel | Managing Director |
Mr. Ganesh N Nayak | Executive Director |
Mr. Bhadresh K Shah | Independent Director |
Mr. Mukesh M Patel | Non Executive Director |
Mr. Nitin R Desai | Independent Director |
Ms. Dharmishtaben N Raval | Independent Woman Director |
Ms. Apurva S Diwanji | Independent Director |
Zydus Lifesciences Forecast
Price Estimates
Zydus Lifesciences Corporate Action
About Company
Zydus Lifesciences FAQs
What is Share Price of Zydus Lifesciences ?
Zydus Lifesciences share price is ₹479 As on 07 February, 2023 | 16:32
What is the Market Cap of Zydus Lifesciences ?
The Market Cap of Zydus Lifesciences is ₹48530.1 Cr As on 07 February, 2023 | 16:32
What is the P/E ratio of Zydus Lifesciences ?
The P/E ratio of Zydus Lifesciences is 23.5 As on 07 February, 2023 | 16:32
What is the PB ratio of Zydus Lifesciences ?
The PB ratio of Zydus Lifesciences is 2.5 As on 07 February, 2023 | 16:32
What were the company's most recent reported sales and net income?
Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20 crores in FY22
What is the future of the company's shares?
Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.
How to buy shares of Zydus Lifesciences Ltd.?
The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.